RIFADIN by Sanofi is mechanism of action rifampin inhibits dna-dependent rna polymerase activity in susceptible mycobacterium tuberculosis organisms. Approved for asymptomatic carriers of neisseria meningitidis to eliminate meningococci from the nasopharynx, meningococcal infection because of the possibility of the rapid emergence of resistant organisms, the treatment of all forms of tuberculosis. First approved in 1971.
Drug data last refreshed 19h ago · AI intelligence enriched 1w ago
RIFADIN (rifampin) is an oral small-molecule antibiotic that inhibits bacterial RNA polymerase, making it bactericidal against Mycobacterium tuberculosis and Neisseria meningitidis. It is indicated for treatment of all forms of tuberculosis and elimination of meningococci in asymptomatic carriers. The drug works by selectively targeting bacterial RNA polymerase while sparing mammalian enzymes.
Product approaching loss of exclusivity with moderate competitive pressure (30/100), indicating likely team restructuring and focus shift toward cost management and pipeline transition planning.
Mechanism of Action Rifampin inhibits DNA-dependent RNA polymerase activity in susceptible Mycobacterium tuberculosis organisms. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme.
Worked on RIFADIN at Sanofi? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on RIFADIN offers limited growth trajectory due to LOE status and mature market position; roles focus on managing decline, defending market share against generics, and optimizing pricing/access. Career value is primarily in gaining experience in LOE management and generic competition strategy rather than launch or growth marketing.